(HCSG) Healthcare - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US4219061086
Stock: Housekeeping, Laundry, Dietary, Maintenance
Total Rating 60
Risk 91
Buy Signal -0.60
| Risk 5d forecast | |
|---|---|
| Volatility | 38.2% |
| Relative Tail Risk | -11.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.40 |
| Alpha | 67.48 |
| Character TTM | |
|---|---|
| Beta | 1.132 |
| Beta Downside | 0.840 |
| Drawdowns 3y | |
|---|---|
| Max DD | 42.54% |
| CAGR/Max DD | 0.38 |
EPS (Earnings per Share)
Revenue
Description: HCSG Healthcare March 04, 2026
Healthcare Services Group Inc. (HCSG) provides outsourced support services to healthcare facilities. These services include housekeeping, laundry, facility maintenance, and dietary management.
The company operates through two segments: Environmental Services, covering cleaning and laundry, and Dietary, which manages food services and provides nutritional consulting. Outsourcing these non-core functions allows healthcare providers to focus on patient care, a common business model in the sector.
HCSG primarily serves long-term care facilities, rehabilitation centers, and hospitals across the United States. The market for outsourced healthcare support services is driven by cost efficiency and specialized expertise.
For more detailed financial analysis and performance metrics, further research on platforms like ValueRay is recommended.
Headlines to watch out for
- Nursing home occupancy rates impact demand for support services
- Labor costs for service staff affect profitability
- Healthcare facility budget constraints limit contract growth
- Regulatory changes in healthcare impact service demand
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 59.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.17 > 0.02 and ΔFCF/TA 14.23 > 1.0 |
| NWC/Revenue: 22.10% < 20% (prev 21.22%; Δ 0.88% < -1%) |
| CFO/TA 0.18 > 3% & CFO 145.0m > Net Income 59.1m |
| Net Debt (-136.4m) to EBITDA (82.8m): -1.65 < 3 |
| Current Ratio: 3.38 > 1.5 & < 3 |
| Outstanding Shares: last quarter (71.6m) vs 12m ago -3.18% < -2% |
| Gross Margin: 13.25% > 18% (prev 0.13%; Δ 1312 % > 0.5%) |
| Asset Turnover: 226.4% > 50% (prev 210.4%; Δ 15.97% > 0%) |
| Interest Coverage Ratio: 33.02 > 6 (EBITDA TTM 82.8m / Interest Expense TTM 2.00m) |
Altman Z'' 5.99
| A: 0.50 (Total Current Assets 576.4m - Total Current Liabilities 170.4m) / Total Assets 807.8m |
| B: 0.35 (Retained Earnings 283.7m / Total Assets 807.8m) |
| C: 0.08 (EBIT TTM 66.0m / Avg Total Assets 811.6m) |
| D: 0.95 (Book Value of Equity 284.0m / Total Liabilities 297.6m) |
| Altman-Z'' Score: 5.99 = AAA |
Beneish M -3.30
| DSRI: 0.82 (Receivables 334.8m/382.3m, Revenue 1.84b/1.72b) |
| GMI: 1.00 (GM 13.25% / 13.29%) |
| AQI: 0.89 (AQ_t 0.25 / AQ_t-1 0.28) |
| SGI: 1.07 (Revenue 1.84b / 1.72b) |
| TATA: -0.11 (NI 59.1m - CFO 145.0m) / TA 807.8m) |
| Beneish M-Score: -3.30 (Cap -4..+1) = AA |
What is the price of HCSG shares?
As of March 11, 2026, the stock is trading at USD 20.14 with a total of 554,967 shares traded.
Over the past week, the price has changed by -5.45%, over one month by +4.68%, over three months by +7.64% and over the past year by +87.17%.
Over the past week, the price has changed by -5.45%, over one month by +4.68%, over three months by +7.64% and over the past year by +87.17%.
Is HCSG a buy, sell or hold?
Healthcare has received a consensus analysts rating of 3.80.
Therefor, it is recommend to hold HCSG.
- StrongBuy: 2
- Buy: 0
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the HCSG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 24 | 19.2% |
| Analysts Target Price | 24 | 19.2% |
HCSG Fundamental Data Overview March 06, 2026
P/E Trailing = 26.3086
P/E Forward = 20.6612
P/S = 0.8172
P/B = 2.9349
P/EG = 1.3592
Revenue TTM = 1.84b USD
EBIT TTM = 66.0m USD
EBITDA TTM = 82.8m USD
Long Term Debt = 9.66m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 5.36m USD (from shortTermDebt, last quarter)
Debt = 24.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -136.4m USD (from netDebt column, last quarter)
Enterprise Value = 1.32b USD (1.50b + Debt 24.7m - CCE 203.9m)
Interest Coverage Ratio = 33.02 (Ebit TTM 66.0m / Interest Expense TTM 2.00m)
EV/FCF = 9.50x (Enterprise Value 1.32b / FCF TTM 139.2m)
FCF Yield = 10.52% (FCF TTM 139.2m / Enterprise Value 1.32b)
FCF Margin = 7.57% (FCF TTM 139.2m / Revenue TTM 1.84b)
Net Margin = 3.21% (Net Income TTM 59.1m / Revenue TTM 1.84b)
Gross Margin = 13.25% ((Revenue TTM 1.84b - Cost of Revenue TTM 1.59b) / Revenue TTM)
Gross Margin QoQ = 16.31% (prev 20.76%)
Tobins Q-Ratio = 1.64 (Enterprise Value 1.32b / Total Assets 807.8m)
Interest Expense / Debt = 1.52% (Interest Expense 374.0k / Debt 24.7m)
Taxrate = 12.98% (8.81m / 67.9m)
NOPAT = 57.5m (EBIT 66.0m * (1 - 12.98%))
Current Ratio = 3.38 (Total Current Assets 576.4m / Total Current Liabilities 170.4m)
Debt / Equity = 0.05 (Debt 24.7m / totalStockholderEquity, last quarter 510.2m)
Debt / EBITDA = -1.65 (Net Debt -136.4m / EBITDA 82.8m)
Debt / FCF = -0.98 (Net Debt -136.4m / FCF TTM 139.2m)
Total Stockholder Equity = 499.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.28% (Net Income 59.1m / Total Assets 807.8m)
RoE = 11.83% (Net Income TTM 59.1m / Total Stockholder Equity 499.4m)
RoCE = 12.97% (EBIT 66.0m / Capital Employed (Equity 499.4m + L.T.Debt 9.66m))
RoIC = 11.51% (NOPAT 57.5m / Invested Capital 499.4m)
WACC = 9.94% (E(1.50b)/V(1.53b) * Re(10.08%) + D(24.7m)/V(1.53b) * Rd(1.52%) * (1-Tc(0.13)))
Discount Rate = 10.08% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -1.53%
[DCF] Terminal Value 74.86% ; FCFF base≈93.3m ; Y1≈112.6m ; Y5≈182.4m
[DCF] Fair Price = 33.50 (EV 2.22b - Net Debt -136.4m = Equity 2.35b / Shares 70.3m; r=9.94% [WACC]; 5y FCF grow 22.11% → 2.90% )
EPS Correlation: 19.79 | EPS CAGR: 33.24% | SUE: 0.75 | # QB: 0
Revenue Correlation: 80.93 | Revenue CAGR: 2.41% | SUE: -0.15 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.24 | Chg7d=+0.002 | Chg30d=+0.004 | Revisions Net=+1 | Analysts=6
EPS current Year (2026-12-31): EPS=0.97 | Chg7d=+0.004 | Chg30d=+0.011 | Revisions Net=+0 | Growth EPS=+19.7% | Growth Revenue=+5.3%
EPS next Year (2027-12-31): EPS=1.11 | Chg7d=+0.006 | Chg30d=-0.046 | Revisions Net=+1 | Growth EPS=+14.4% | Growth Revenue=+5.2%
[Analyst] Revisions Ratio: +0.33 (2 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.3% (Discount Rate 10.1% - Earnings Yield 3.8%)
[Growth] Growth Spread = -1.6% (Analyst 4.7% - Implied 6.3%)
P/E Forward = 20.6612
P/S = 0.8172
P/B = 2.9349
P/EG = 1.3592
Revenue TTM = 1.84b USD
EBIT TTM = 66.0m USD
EBITDA TTM = 82.8m USD
Long Term Debt = 9.66m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 5.36m USD (from shortTermDebt, last quarter)
Debt = 24.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -136.4m USD (from netDebt column, last quarter)
Enterprise Value = 1.32b USD (1.50b + Debt 24.7m - CCE 203.9m)
Interest Coverage Ratio = 33.02 (Ebit TTM 66.0m / Interest Expense TTM 2.00m)
EV/FCF = 9.50x (Enterprise Value 1.32b / FCF TTM 139.2m)
FCF Yield = 10.52% (FCF TTM 139.2m / Enterprise Value 1.32b)
FCF Margin = 7.57% (FCF TTM 139.2m / Revenue TTM 1.84b)
Net Margin = 3.21% (Net Income TTM 59.1m / Revenue TTM 1.84b)
Gross Margin = 13.25% ((Revenue TTM 1.84b - Cost of Revenue TTM 1.59b) / Revenue TTM)
Gross Margin QoQ = 16.31% (prev 20.76%)
Tobins Q-Ratio = 1.64 (Enterprise Value 1.32b / Total Assets 807.8m)
Interest Expense / Debt = 1.52% (Interest Expense 374.0k / Debt 24.7m)
Taxrate = 12.98% (8.81m / 67.9m)
NOPAT = 57.5m (EBIT 66.0m * (1 - 12.98%))
Current Ratio = 3.38 (Total Current Assets 576.4m / Total Current Liabilities 170.4m)
Debt / Equity = 0.05 (Debt 24.7m / totalStockholderEquity, last quarter 510.2m)
Debt / EBITDA = -1.65 (Net Debt -136.4m / EBITDA 82.8m)
Debt / FCF = -0.98 (Net Debt -136.4m / FCF TTM 139.2m)
Total Stockholder Equity = 499.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.28% (Net Income 59.1m / Total Assets 807.8m)
RoE = 11.83% (Net Income TTM 59.1m / Total Stockholder Equity 499.4m)
RoCE = 12.97% (EBIT 66.0m / Capital Employed (Equity 499.4m + L.T.Debt 9.66m))
RoIC = 11.51% (NOPAT 57.5m / Invested Capital 499.4m)
WACC = 9.94% (E(1.50b)/V(1.53b) * Re(10.08%) + D(24.7m)/V(1.53b) * Rd(1.52%) * (1-Tc(0.13)))
Discount Rate = 10.08% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -1.53%
[DCF] Terminal Value 74.86% ; FCFF base≈93.3m ; Y1≈112.6m ; Y5≈182.4m
[DCF] Fair Price = 33.50 (EV 2.22b - Net Debt -136.4m = Equity 2.35b / Shares 70.3m; r=9.94% [WACC]; 5y FCF grow 22.11% → 2.90% )
EPS Correlation: 19.79 | EPS CAGR: 33.24% | SUE: 0.75 | # QB: 0
Revenue Correlation: 80.93 | Revenue CAGR: 2.41% | SUE: -0.15 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.24 | Chg7d=+0.002 | Chg30d=+0.004 | Revisions Net=+1 | Analysts=6
EPS current Year (2026-12-31): EPS=0.97 | Chg7d=+0.004 | Chg30d=+0.011 | Revisions Net=+0 | Growth EPS=+19.7% | Growth Revenue=+5.3%
EPS next Year (2027-12-31): EPS=1.11 | Chg7d=+0.006 | Chg30d=-0.046 | Revisions Net=+1 | Growth EPS=+14.4% | Growth Revenue=+5.2%
[Analyst] Revisions Ratio: +0.33 (2 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.3% (Discount Rate 10.1% - Earnings Yield 3.8%)
[Growth] Growth Spread = -1.6% (Analyst 4.7% - Implied 6.3%)